Chengdu Ruier Pharmaceutical Technology

Chengdu Ruier Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Chengdu, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets oncology indications, with a lead program, RE-024, which is a highly selective CDK4/6 inhibitor designed to treat advanced breast cancer and other solid tumors. Ruier Pharmaceutical leverages its internal R&D capabilities to advance a pipeline of candidates through various stages of clinical development. The company aims to address unmet medical needs by providing more effective and safer treatment options for cancer patients. Its research efforts are supported by a team of experienced scientists with backgrounds in medicinal chemistry and pharmacology.